Antag Therapeutics

Therapeutic peptides for the modulation of GIP biology

Antag Therapeutics is a biotechnology company dedicated to developing innovative peptide-based therapies to address obesity and related cardiometabolic disorders.

Our approach is rooted in decades of pioneering research from the University of Copenhagen, with a focus on the complexities of incretin physiology. Antag’s portfolio of GIPR antagonists is inspired by an endogenous GIPR antagonist discovered by the esteemed research teams of Professors Jens Juul Holst and Mette Rosenkilde, extensively studied in numerous human interventional trials.

Focus area

Obesity

According to the WHO, over 890 million adults globally suffer from obesity—a number that continues to rise each year. Obesity is a major driver of serious comorbidities, including type 2 diabetes, fatty liver disease, stroke, coronary artery disease, and cancer, among others. While recent advancements in obesity treatments have delivered promising results, there remains a critical need for complementary therapies to address diverse patient needs and challenges such as accessibility, tolerability, and long-term adherence.

At Antag Therapeutics, we are dedicated to transforming the treatment landscape by developing innovative GIPR antagonist therapies to combat obesity and offer new solutions for patients worldwide.

Our first-in-class therapeutic peptides are optimized analogues of an inhibitor of the GIP receptor that is found naturally in the human body

Team

Philip Just Larsen
MD, PhD
Chair
CEO of 6 Peaks Bio with 20 years of experience leading research divisions within the pharmaceutical industry.

Mark Currie
M.Sc., PhD
Independent
Ironwood BoD, inventor of linaclotide and built and led Ironwood R&D, Co-Founder and President of Cyclerion and inventor of multiple drugs in clinical dev. and currently serves as Chair of SAB

Jørgen Søberg
MD, PhD, DMSc, MBA
Senior Partner at Novo Holdings with several significant exits. Co-founder and former CSO of Zealand Pharma. Executive R&D roles at Lundbeck, Merck, and Novo Nordisk.

Alexander Mayweg
M.Sc., PhD
Managing Director at Versant Ventures and president of Ridgeline, and has launched and exited several biotech companies, with 14 years prior experience at Roche leading global drug discovery.

Amit Shah
M.Sc. MD
Principal at SR One, previously at GSK in R&D and commercial roles in immunology franchise. Former practising MD.

Alexander H. Sparre-Ulrich
Chief Executive Officer
M.Sc. PhD
Award winning innovator that has led all commercialization and R&D activities since company inception.

Mads T. Christensen
Chief Scientific Officer
MD PhD
Former Corporate Vice President of Global Obesity and Liver Disease at Novo Nordisk

Richard Nkulikiyinka
Chief Medical Officer
MSc, MB BChir, MRCP
Former Vice President, Head of Therapeutic Area Cardiology, Nephrology & Pulmonology at Bayer

John Boland
Vice President, Clinical Operations
Over 20+ years of regulatory, strategic, and clinical operations experience within autonomic diseases

Sandra C. Cottrell
Head of Regulatory Strategy
M.Sc. PhD
Over 35+ years of regulatory experience (JNJ, Novo Nordisk, NPS Pharm, Chugai, etc.)

Jakob Dynnes Hansen
Chief Financial Officer
M.Sc., MBA
Has more than 25 years of combined experience from biotech and financing.

Ingrid Brück Bøgh
Vice President, Toxicology and Safety
D.V.Sc., PhD
Former Vice President of Toxicology and Safety at Novo Nordisk and Professor of Veterinary Sciences

Kaare G. Rasmussen
Head of Chemical Development
M.Sc. PhD
Has more than 20 years of CMC experience with a focus on drug manufacturing and project management

René Egebro
Head of Pharmaceutical Development
M.Sc.
Has more than 20 years of CMC experience with a focus on drug product- and analytical development

Mette Høy Jensen
Director Scientific Affairs
M.Sc., Ph.D.
Has more than seven years of Biotech experience running preclinical and clinical studies

News

Antag Therapeutics Announces €80 Million Series A Financing

DECEMBER 4, 2024

“Antag Therapeutics, a next-generation biopharmaceutical company pioneering novel treatments for obesity, today announced the closing of an €80 million Series A financing. The round was led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn Biopharma (a platform controlled by KKR), Pictet, Longview Ventures (an affiliate of Broadview Ventures), and Export and Investment Fund of Denmark (EIFO)…”

Read more

Antag Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Lead Molecule, AT-7687

OCTOBER 9, 2024

“We are thrilled to receive the FDA’s acceptance of our IND application for AT-7687,” said Alexander Sparre-Ulrich, CEO of Antag Therapeutics. “This marks a major step forward in advancing our clinical development program and brings us closer to providing a potential new treatment for patients with obesity and cardiometabolic diseases. We are excited to begin our Phase I study and further demonstrate the therapeutic potential of AT-7687 and GIPR antagonism.”

Read more

Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors

JULY 15, 2021

Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors.

Read more

Novo Seeds invests millions in diabetes venture with huge potential

JUNE 26, 2017

Denmark’s largest business newspaper (Børsen) covers Antag Therapeutic’s launch in this article

Read more

Novo Seeds invests millions in new venture

JUNE 26, 2017

MedWatch.dk covers the launch of Antag Therapeutics in the following article in Danish.

Read more